2009
Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study
Rathore SS, Curtis JP, Chen J, Wang Y, Nallamothu BK, Epstein AJ, Krumholz HM, Registry F. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. The BMJ 2009, 338: b1807. PMID: 19454739, PMCID: PMC2684578, DOI: 10.1136/bmj.b1807.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionElevation myocardial infarctionPercutaneous coronary interventionBalloon timeCoronary interventionMyocardial infarctionCohort studyLower mortalityMultivariable logistic regression modelAssociation of doorIncremental mortality benefitProspective cohort studyNational cohort studyAcute care hospitalsLogistic regression modelsFractional polynomial modelsAdjusted riskLonger doorMedian doorMortality benefitCare hospitalOverall mortalityMAIN OUTCOMEAmerican College
2006
Impact of Medication Therapy Discontinuation on Mortality After Myocardial Infarction
Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of Medication Therapy Discontinuation on Mortality After Myocardial Infarction. JAMA Internal Medicine 2006, 166: 1842-1847. PMID: 17000940, DOI: 10.1001/archinte.166.17.1842.Peer-Reviewed Original ResearchConceptsTherapy discontinuationMyocardial infarctionEvidence-based medicationsMulticenter prospective cohortUse of aspirinMultivariable survival analysisTransitions of careDiscontinuation of useProspective registryMortality benefitProspective cohortMultivariable analysisOutpatient settingMI hospitalizationDiscontinuationMortality riskMedicationsPatientsSurvival analysisHigh mortalityMortalityTreatment factorsMonthsInfarctionAspirin
2003
Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure. JAMA 2003, 289: 871-878. PMID: 12588271, DOI: 10.1001/jama.289.7.871.Peer-Reviewed Original ResearchConceptsSerum digoxin concentrationHigh serum digoxin concentrationsLeft ventricular ejection fractionVentricular ejection fractionHeart failureMortality rateDIG trialDigoxin therapyEjection fractionDigoxin concentrationsDepressed left ventricular systolic functionDigitalis Investigation Group trialHigher absolute mortality rateLeft ventricular systolic functionOverall mortality benefitVentricular systolic functionCause mortality ratesAbsolute mortality ratesLower mortality rateCause mortalityMultivariable adjustmentMortality benefitSystolic functionClinical outcomesSerum concentrations
2002
β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction
Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. β-Blocker Therapy and Symptoms of Depression, Fatigue, and Sexual Dysfunction. JAMA 2002, 288: 351-357. PMID: 12117400, DOI: 10.1001/jama.288.3.351.Peer-Reviewed Original ResearchConceptsBeta-blocker therapySexual dysfunctionDepressive symptomsSymptoms of depressionAdverse eventsHeart failureMyocardial infarctionSignificant annual increaseAdditional reportsLipid solubilityAdverse effectsWithdrawal of therapyΒ-blocker therapyPatient-reported symptomsNumber of patientsEnglish-language articlesInclusion of trialsPlacebo groupMortality benefitRandomized trialsStudy treatmentCardiac patientsPlacebo controlRisk of fatigueClinical trialsβ-Blocker Therapy in Heart Failure: Scientific Review
Foody JM, Farrell MH, Krumholz HM. β-Blocker Therapy in Heart Failure: Scientific Review. JAMA 2002, 287: 883-889. PMID: 11851582, DOI: 10.1001/jama.287.7.883.Peer-Reviewed Original ResearchConceptsHeart failure patientsHeart failureClinical trialsFailure patientsClinical outcomesClass IIDrug Administration indicationsBeta-blocker usePrimary end pointΒ-blocker therapyScientific rationaleTreatment of patientsCare of patientsEnglish-language articlesPotential physiologic roleBasic science studiesClass of agentsSystolic dysfunctionMortality benefitPlacebo treatmentDATA EXTRACTIONClinical guidelinesSTUDY SELECTIONCurrent recommendationsPatients